Biocon And Viatris Get CRL From FDA On Insulin Aspart

Biosimilar Rival To NovoLog Already Approved In Europe As Kixelle

 
• By Dave Wallace

Viatris and partner Biocon have suffered a setback over their proposed insulin aspart biosimilar rival to NovoLog in the US, after the FDA issued a CRL relating to the filing.

Sign outside of FDA's headquarters in White Oak, MD
The FDA has issued a CRL over the proposed NovoLog rival • Source: Alamy

More from Biosimilars

More from Products